功能精准癌症医学：基于细胞培养模型的药物敏感性筛选。

Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models.

机构信息

The Cancer Clinic, St. Olav University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

出版信息

Trends Pharmacol Sci. 2022 Nov;43(11):973-985. doi: 10.1016/j.tips.2022.08.009. Epub 2022 Sep 23.

DOI:10.1016/j.tips.2022.08.009

PMID:36163057

Abstract

Functional precision medicine is a new, emerging area that can guide cancer treatment by capturing information from direct perturbations of tumor-derived, living cells, such as by drug sensitivity screening. Precision cancer medicine as currently implemented in clinical practice has been driven by genomics, and current molecular tumor boards rely extensively on genomic characterization to advise on therapeutic interventions. However, genomic biomarkers can only guide treatment decisions for a fraction of the patients. In this review we provide an overview of the current state of functional precision medicine, highlight advances for drug-sensitivity screening enabled by cell culture models, and discuss how artificial intelligence (AI) can be coupled to functional precision medicine to guide patient stratification.

摘要

功能精准医学是一个新兴领域，可以通过获取肿瘤来源的活细胞直接扰动的信息（如药物敏感性筛选）来指导癌症治疗。目前在临床实践中实施的精准癌症医学是由基因组学驱动的，当前的分子肿瘤委员会广泛依赖基因组特征来提供治疗干预建议。然而，基因组生物标志物只能为一部分患者的治疗决策提供指导。在这篇综述中，我们概述了功能精准医学的现状，强调了基于细胞培养模型的药物敏感性筛选的进展，并讨论了人工智能 (AI) 如何与功能精准医学相结合，以指导患者分层。